#Japan #Tokyo #N-NOSE #HIROTSU BioScience #Japan Sumo Association

A Reflective Dialogue: HIROTSU BioScience and Sumo

In an extraordinary conversation between HIROTSU BioScience's CEO, Takasumi Hirotsu, and the Chairman of the Japan Sumo Association, Nobuyoshi Hakkaku, published in the March 13, 2026, issue of Yomiuri Shimbun, the two leaders shared insights into their 10-year journey of innovation and collaboration.

This dialogue occurs during the March Grand Sumo Tournament, highlighting the company’s significant role as an official partner of the Japan Sumo Association. They have worked diligently to support members' health, particularly through the development of the cancer risk detection system known as N-NOSE. This year not only marks a decade since N-NOSE's inception but also a decade since Chairman Hakkaku's tenure.

Evolution of N-NOSE

The discussion emphasizes the evolution of N-NOSE and its societal impact over the past ten years. It encapsulates how HIROTSU BioScience has enhanced accessibility for cancer screenings. Innovations include allowing patients to collect samples in the comfort of their homes and submitting them through a mail service, which has greatly improved usability and convenience. The founders' aspiration to protect the health of as many individuals as possible continues to resonate through these advancements.

Shared Mission: Empowering Others

During this dialogue, both leaders articulate their roles within society, emphasizing the importance of service and connection. Despite their divergent paths, they resonate deeply with the desire to be a source of strength for others. Their conversation illustrates the responsibility they feel towards society's health literacy and how these principles guide their endeavors.

About HIROTSU BioScience

Founded in August 2016, HIROTSU BioScience is dedicated to developing and implementing groundbreaking testing technologies harnessed from the unique capabilities of organisms. With a mission to safeguard public health and future security, the company has pioneered the use of C. elegans, a nematode with an extraordinary sense of smell, in cancer detection. In an era where one in two individuals may be diagnosed with cancer, this technology offers vital solutions to pressing health challenges.

HIROTSU BioScience operates from the New Otani Garden Court in Chiyoda, Tokyo. The challenges of extending healthy lifespans in a world where longevity is becoming the norm drive their innovative pursuits. As cancer research and development continue to evolve, N-NOSE remains at the forefront, showcasing the potential of bioscience in advancing public health.

N-NOSE: The Cancer Risk Detection Revolution

The N-NOSE technology stands out as a pioneering solution relying on C. elegans to detect cancer-related odors present in human urine. This easy, affordable, and high-precision screening method allows for comprehensive early detection of cancer risks simply by submitting a urine sample.
You can learn more about N-NOSE at N-NOSE Service Site.

Through their collaboration, HIROTSU BioScience and the Japan Sumo Association continue to pioneer a path towards a healthier future, showcasing the impact of science and community on individual well-being.